Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 20/20 | 0.95 |
| ▸ | CCNE1 | P24864 | 20/20 | 0.95 |
| ▸ | CDK2 | P24941 | 20/20 | 0.95 |
| ▸ | CDK6 | Q00534 | 20/20 | 0.95 |
| ▸ | CDK4 | P11802 | 7/20 | 0.95 |
| ▸ | CCND3 | P30281 | 6/20 | 0.95 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.95 |
| ▸ | CDK9 | P50750 | 4/20 | 0.95 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.95 |
| ▸ | RB1 | P06400 | 1/20 | 0.95 |
| ▸ | CDK1 | P06493 | 1/20 | 0.95 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ebvaciclib SCHEMBL19863683 | 0.98 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL29359734 | 0.98 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL19880088 | 0.98 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550182 | 0.98 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL19857421 | 0.98 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550073 | 0.92 | CCND1 (0.89) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550079 | 0.92 | CCND1 (0.89) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550154 | 0.92 | CCND1 (0.89) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550180 | 0.91 | CCND1 (0.88) | CCND1CCNE1CDK2CDK6CDK4 | |
| SCHEMBL19863694 | 0.91 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220127262-A1 | CRYSTALLINE FORM OF A CDK INHIBITOR | PFIZER INC. (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCND1 40/4885CCNE1 29/4885CDK2 1/4885 |
| US-20220127262-A1 | CRYSTALLINE FORM OF A CDK INHIBITOR | CDK6, CDK7, CDK2 | CCND1 39/4885CCNE1 43/4885CDK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.